Skip to Main Content

In an about-face, Teva Pharmaceutical is resuming supplies of a critical cancer medicine for children after its recent decision to discontinue production contributed to a shortage that alarmed patients and physicians. As a result, vincristine will be available as early in 2020 “as possible.”

“Because vincristine is such a lifesaving medicine — and there is no reliable single supply anticipated in the near term — we have decided to re-introduce the product and plan to manufacture it in our plant in the U.S., which provides the fastest route to market,” the drug maker said in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!